Impact on Outcome of Different Mechanisms, Baseline Degree and Changes of Mitral Regurgitation in Patients With Aortic Stenosis Who Underwent Transcatheter Aortic Valve Replacement.

aortic stenosis mitral regurgitation transcatheter aortic valve implantation

Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
09 Jul 2024
Historique:
medline: 9 7 2024
pubmed: 9 7 2024
entrez: 9 7 2024
Statut: aheadofprint

Résumé

Mitral regurgitation (MR) is frequent in patients with aortic stenosis (AS). Although primary MR is an established negative prognostic factor, whether different mechanisms of MR have different effects on outcome is currently unknown. The aim of this study was to evaluate the impact of the MR mechanism in patients undergoing transcatheter aortic valve replacement (TAVR). This is a retrospective observational study of patients who underwent TAVR for severe aortic stenosis in a high-volume tertiary care center. Echocardiographic comprehensive MR assessment was performed at baseline and within 3 months post TAVR. The study population was divided into 4 groups according to MR mechanism: Group I: fibro-calcific leaflet degeneration; Group II: prolapse/flail; Group III: ventricular secondary MR (functional MR); and Group IV: atrial functional MR. The study end point was a combination of death from cardiovascular cause and heart failure-related hospitalization. The study population included 427 patients (mean age 81.7±6.5 years; 71% primary MR; 62% ≥moderate MR). At 3-year follow-up, survival free from the composite end point significantly differs according to MR mechanism: it was higher in group IV (atrial functional MR, 96.6%) compared with group I (80.4%, In patients undergoing TAVR, preprocedural identification of MR mechanism and mechanism provides prognostic insights.

Sections du résumé

BACKGROUND BACKGROUND
Mitral regurgitation (MR) is frequent in patients with aortic stenosis (AS). Although primary MR is an established negative prognostic factor, whether different mechanisms of MR have different effects on outcome is currently unknown. The aim of this study was to evaluate the impact of the MR mechanism in patients undergoing transcatheter aortic valve replacement (TAVR).
METHODS AND RESULTS RESULTS
This is a retrospective observational study of patients who underwent TAVR for severe aortic stenosis in a high-volume tertiary care center. Echocardiographic comprehensive MR assessment was performed at baseline and within 3 months post TAVR. The study population was divided into 4 groups according to MR mechanism: Group I: fibro-calcific leaflet degeneration; Group II: prolapse/flail; Group III: ventricular secondary MR (functional MR); and Group IV: atrial functional MR. The study end point was a combination of death from cardiovascular cause and heart failure-related hospitalization. The study population included 427 patients (mean age 81.7±6.5 years; 71% primary MR; 62% ≥moderate MR). At 3-year follow-up, survival free from the composite end point significantly differs according to MR mechanism: it was higher in group IV (atrial functional MR, 96.6%) compared with group I (80.4%,
CONCLUSIONS CONCLUSIONS
In patients undergoing TAVR, preprocedural identification of MR mechanism and mechanism provides prognostic insights.

Identifiants

pubmed: 38979804
doi: 10.1161/JAHA.123.033125
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e033125

Auteurs

Francesco Melillo (F)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.
Echo Lab, Clinica Montevergine, GVM Care and Research Mercogliano Italy.
Cardiovascular Research Institute (CARIM) University of Maastricht Maastricht Netherlands.

Annamaria Tavernese (A)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.

Vincenzo Rizza (V)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.

Francesco Putortì (F)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.

Alberto Preda (A)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.

Francesco Ancona (F)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.

Giacomo Ingallina (G)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.

Stefano Stella (S)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.

Antonio Colombo (A)

Interventional Cardiology Unit Humanitas Research Hospital Milan Italy.

Marco Ancona (M)

Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute Milan Italy.

Alaide Chieffo (A)

Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute Milan Italy.
Heart Valve Centre IRCCS San Raffaele Scientific Institute Milan Italy.
Vita-Salute San Raffaele University Milan Italy.

Nicola Buzzatti (N)

Heart Valve Centre IRCCS San Raffaele Scientific Institute Milan Italy.

Alessandro Castiglioni (A)

Heart Valve Centre IRCCS San Raffaele Scientific Institute Milan Italy.
Vita-Salute San Raffaele University Milan Italy.

Michele De Bonis (M)

Heart Valve Centre IRCCS San Raffaele Scientific Institute Milan Italy.
Vita-Salute San Raffaele University Milan Italy.

Francesco Maisano (F)

Heart Valve Centre IRCCS San Raffaele Scientific Institute Milan Italy.
Vita-Salute San Raffaele University Milan Italy.

Matteo Montorfano (M)

Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute Milan Italy.
Vita-Salute San Raffaele University Milan Italy.

Eustachio Agricola (E)

Cardiovascular Imaging Unit, Cardio-Thoracic-Vascular Department IRCCS San Raffaele Scientific Institute Milan Italy.
Vita-Salute San Raffaele University Milan Italy.

Classifications MeSH